Breast cancer (2)
C20 – C60
- C20: INSPIRE: An integrated web based informatics infrastructure for automated analysis of laboratory and clinical data
- C21: A longitudinal study of the psychosocial impact of a diagnosis of ductal carcinoma in situ
- C22: Prospective audit of questionnaire to assess chemotherapy toxicity
- C23: Obesity in postmenopausal women with a family history of breast cancer
- C24: Factors associated with high mastectomy rates in a UK specialist centre
- C25: The total hospital and community UK costs of managing patients with relapsed breast cancer
- C26: Changes in metastatic breast cancer management over 5 years – costs and outcomes
- C27: Is there a role for hospital based early breast cancer follow-up clinics beyond 3 years?
- C28: Variation in the provision of immediate breast reconstruction in England
- C29: Case controlled, cross-sectional survey of joint and muscle aches, pains and stiffness in women with primary breast cancer
- C30: How does radiotherapy affect body Image, breast and arm symptoms of women with early stage breast cancer? Patient reported outcomes from the START Trials (UK Standardisation of Breast Radiotherapy)
- C31: The IMPORT LOW Quality of Life Study: what we have learnt from the START Trial?
- C32: How much do age, clinical and psychological factors contribute to fatigue following radiotherapy for early breast cancer? Evidence from the START Trials (UK Standardisation of Breast Radiotherapy)
- C33: MR Imaging in breast cancer – results of the COMICE trial
- C34: MRC SUPREMO (BIG 2-04/EORTC 22051) - a phase III randomised trial assessing the role of postmastectomy radiotherapy in intermediate risk breast cancer
- C35: Selective axillary node sampling and radiotherapy to the axilla for breast cancer: minimising morbidity and avoiding delays in initiation of systemic therapy
- C36: Differential effects of ionising radiation on p53 and its isoforms in the breast cancer cell line MCF7
- C37: Effects of radiation combined with letrozole or tamoxifen in aromatase transfected MCF7
- C38: Is there a subset of women at increased risk of lymphoedema after breast cancer treatment?
- C39: A-769662 is an AMP Kinase-dependant growth inhibitor in breast cancer cell lines
- C40: The nitrogen-containing bisphosphonate Zoledronic acid (Zol) inhibits Cenp-F farnesylation leading to impaired chromosome separation in breast cancer cells
- C41: Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch™ BLN Assay in the operating room: results of the Cardiff validation study
- C42: Anti-HER2 Diabody for Breast Cancer Imaging: GMP-compliant Production and Preliminary product Analysis
- C43: Reduced expression of BMPRIB in breast cancer correlates with poor prognosis
- C44: Polysomy of chromosome 17 is associated with a reduced relapse-free survival in HER2 amplified tumours
- C45: Validation of cleaved caspase-3 antibody staining as a marker of apoptosis in breast cancer
- C46: Proximity ligation assay detects HER2 homo- and heterodimers in human breast cancer
- C47: New highlights on the biological, clinical, and prognostic implications of p53 transcriptional status in breast cancers
- C48: p53 mutation is associated with deprivation and poor prognosis in primary breast cancer
- C49: Molecular subtypes of breast cancer and prognosis
- C50: Differences in breast cancer risk factors by tumour marker subtypes in Pakistani women
- C51: PLGF1 and 2 as prognostic indicators in human colorectal carcinoma
- C52: FABP7 expression predicts better outcome in basal-like breast cancer
- C53: Relationship of RT-PCR with standard techniques for diagnostics of ER and HER2 in FFPE breast cancer
- C54: Metastatic breast cancer correlates with the expression of aB-crystallin and vimentin, but not HSP27
- C55: UPARAP/Endo180 expression in invasive breast carcinoma and its relation to patient outcome
- C56: An inherited genetic polymorphism in the oestrogen receptor gene is associated with poor prognosis in young breast cancer patients
- C57: Comparison of high-resolution melt curve technology (HRM) and quantitative multiplex methylation specific PCR (QM-MSP) for analysis of cell-free plasma DNA samples from breast cancer patients
- C58: Effects of p53 abrogation on doxorubicin response in an MCF7 breast cancer xenograft model
- C59: Investigating the role of Fibroblast growth factor 2 in breast cancer
- C60: Optical proteomics can profile breast cancer specimens, potentially personalizing prognosis and treatment for individual patients
